Back to search

Article

Recent Advances in Pre-clinical Development of Adiponectin Receptor Agonist Therapies for Duchenne Muscular Dystrophy

2024-05-01

Abstract excerpt

Duchenne muscular dystrophy (DMD) is caused by genetic mutations in the cytoskeletal-sarcolemmal anchor protein dystrophin. Repeated cycles of sarcolemmal tearing and repair lead to a variety of secondary cellular and physiological stressors that are thought to contribute to weakness, atrophy, and fibrosis. Collectively, these stressors can contribute to a pro-inflammatory milieu in locomotor, cardiac, and respira...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d7bd8276-e27e-5cb9-83f6-d9105653d36e
DOI
10.20944/preprints202405.0015.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Recent Advances in Pre-clinical Development of Adiponectin Receptor Agonist Therapies for Duchenne Muscular DystrophyDOI 10.20944/preprints202405.0015.v1
An Overview of Recent Therapeutics Advances for Duchenne Muscular Dystrophy.Semantic proximity
The adiponectin analogue ALY688-SR attenuates diaphragm fibrosis, atrophy and mitochondrial stress in a mouse model of Duchenne muscular dystrophySemantic proximity
Emerging drugs for Duchenne muscular dystrophySemantic proximity
Molecular and Biochemical Therapeutic Strategies for Duchenne Muscular DystrophySemantic proximity
Improving the therapeutic efficacy of gene therapy for duchenne muscular dystrophy (DMD) by evaluating and managing inflammationSemantic proximity
Duchenne muscular dystrophy: pathogenesis and promising therapies.Semantic proximity
AdipoRon , a new therapeutic prospect for Duchenne muscular dystrophySemantic proximity
The glucocorticoid receptor acts locally to protect dystrophic muscle and heart during disease.Semantic proximity
Mitochondria in Duchenne Muscular Dystrophy-induced Cardiomyopathy: A Prospective Therapeutic Target to Improve Treatment ResponseSemantic proximity
VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects.Semantic proximity
Muscle and cardiac therapeutic strategies for Duchenne muscular dystrophy: past, present, and future.Semantic proximity
Potential Adiponectin Receptor Response Modifier TherapeuticsSemantic proximity
Select a neighboring publication to make it the new centre.